This program is supported by an independent medical education grant from Jazz Pharmaceuticals.
Meet the Faculty:
Richard K. Bogan MD, FCCP, FAASM
Associate Clinical Professor
University of South Carolina School of Medicine
Principal, Bogan Sleep Consultants, LLC
Columbia, SC
Introduction:
June 9th, 2025:
Abstracts:
Nocturnal Spontaneous Arousals in People With Narcolepsy and Idiopathic Hypersomnia Treated With Low-Sodium Oxybate
Prevalence and Severity of Sleep Inertia Among Individuals with Idiopathic Hypersomnia
Impact of Switching from High- to Low-Sodium Oxybate on Ambulatory Blood Pressure in Patients with Narcolepsy
Effectiveness and Safety of Low-Sodium Oxybate Dosages Greater Than 9 Grams in Study Participants With Narcolepsy
June 10th, 2025:
Poster Presentations:
Evaluation of Dreem 3S for Sleep Monitoring in Narcolepsy Type 1
Accelerometry Assessment of Factors Related to how TAK-861 Affects Disrupted Sleep in People with Narcolepsy Type 1
Nocturnal Spontaneous Arousals in People With Narcolepsy and Idiopathic Hypersomnia Treated With Low-Sodium Oxybate
Real-World, Participant-Reported Effectiveness and Satisfaction with Low-Sodium Oxybate in Idiopathic Hypersomnia
Real-World Surveys of Treatment Effectiveness and Satisfaction in Adults with Narcolepsy Taking Low-Sodium Oxybate
Impact of Switching from High- to Low-Sodium Oxybate on Ambulatory Blood Pressure in Patients with Narcolepsy
Effectiveness and Safety of Low-Sodium Oxybate Dosages Greater Than 9 Grams in Study Participants With Narcolepsy
Prevalence and Severity of Sleep Inertia Among Individuals with Idiopathic Hypersomnia
Qualitative Assessment of the Patient Experience of Idiopathic Hypersomnia: Implications for Evaluating Treatment Efficacy in Clinical Trials
Vibrance-3: Study Design and Methods for a Phase 2, Randomized, Placebo Controlled, Parallel-Group Study Evaluating the Safety and Efficacy of ALKS 2680 in Patients With Idiopathic Hypersomnia
Social Determinants of Health and Clinical Burden in Narcolepsy: A Retrospective Cohort Analysis
Demographic and Clinical Characteristics in Narcolepsy and Idiopathic Hypersomnia at Treatment Initiation
Evaluating the Impact of Patient Support Group Events in Narcolepsy Patients
June 11th, 2025:
Abstracts:
Disclosures:
Dr. Bogan reports the following financial relationships:
Consultant: Alkermes; Apnimed, Inc.; Avadel; Daiichi Sankyo, Inc.; Eisai Inc.; Harmony Biosciences; and Takeda Pharmaceutical Company Limited
Research Support: Apnimed, Inc.; AstraZeneca; Avadel; Axsome Therapeutics, Inc.; Balance; Bayer; Bresotec Medical; Centessa Pharmaceuticals; Eisai Inc.; Fisher & Paykel Healthcare Limited; Fresca Medical, Inc.; Idorsia Pharmaceuticals; Insilico Medicine; Jazz Pharmaceuticals, Inc.; LivaNova; Merck & Co., Inc.; Mineralys Therapeutics, Inc.; NLS Pharmaceutics; Noctrix; Oura; Philips; Rho, Inc.; Roche; Sanofi; Sommetrics, Inc.; Suven Life Sciences; Takeda Pharmaceutical Company Limited; Zevra Therapeutics; and ZiO Health Ltd
Speakers Bureau for Axsome Therapeutics, Inc.; Eisai Inc.; Harmony Biosciences; Idorsia Pharmaceuticals; and Jazz Pharmaceuticals, Inc.
Shareholder: Healthy Humming, LLC and Watermark Medical
Board of Directors: Watermark Medical